Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of GVAX in Colorectal Cancer Cells

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically documented hepatic colorectal cancer metastasis with resectable hepatic lesions~* At least 4 weeks since last dose of chemotherapy, radiotherapy, immunotherapy, systemic glucocorticoid therapy or operation in order to receive vaccine~* Fully recovered from hepatic resection~Exclusion Criteria:~* Pregnant or breastfeeding~* Uncontrolled active infection~* Infection with HIV, Hepatitis B or C~* Other current malignancies except in situ cancer or basal/squamous cell carcinoma~* Active autoimmune disease~* Hepatic metastases involving both branches of the portal vein or all three hepatic veins~* Peritoneal metastases identified at the time of attempted resection~* Greater than 1 month since resection of liver metastasis for vaccine production

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Treatment Arm (Type: EXPERIMENTAL): GVAX, up to 6 vaccinations, administered via injection

Based on this trial design, predict the completion outcome and termination type (if applicable).